ROCKVILLE, Md., Jan. 25 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that the company will be presenting at the upcoming Phacilitate Vaccine Forum Washington 2010. The Conference will take place January 25-27, 2010 at the Grand Hyatt, Washington, D.C. Mr. John Trizzino, Senior Vice President of International and Government Alliances will be participating in a Focus Session: Fast Tracking the development of - and path to licensure for - a novel manufacturing platform by utilizing it in pandemic influenza efforts on January 26, 2010 at 4:15pm.

Dr. Rahul Singhvi, President and CEO will be presenting a Case Study: Small Company/Big Company interplay: How does it all connect around manufacturing, supply chain, and the need for dose sparing? on January 27, 2010 at 12:55 pm.

About Vaccine Forum Washington 2010

The conference program features a highly stimulating mixture of business, regulatory, investment and public policy topics, with the speaker panel featuring high level representatives of vaccine developers themselves, as well as key government agencies, non-government agencies and analysts. For more information visit: www.phacilitate.co.uk

About Novavax

Novavax, Inc. is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com.

SOURCE Novavax, Inc.